

available at www.sciencedirect.com
journal homepage: www.europeanurology.com



European Association of Urology



Prostate Cancer

Sensitivity and Detection Rate of A 12-Core Trans-Perineal Prostate Biopsy: Preliminary Report

Bernardo Rocco^{a,*}, Ottavio de Cobelli^a, Maria Elena Leon^b, Mario Ferruti^c,
Mauro G. Mastropasqua^d, Deliu Victor Matei^a, Giacomo Gazzano^e, Fabrizio Verweij^a,
Epifanio Scardino^a, Gennaro Musi^c, Bob Djavan^f, Francesco Rocco^c

^aDivision of Urology, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy

^bDivision of Epidemiology and Biostatistics, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy

^cDepartment of Clinical Urology, University of Milan, Via Commenda 5, 20122 Milan, Italy

^dDivision of Pathology and Laboratory Medicine, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy

^eDivision of Pathology, Ospedale S. Paolo, Via di Rudini 8, Milan, Italy

^fDivision of Urology, University of Vienna, Vienna, Austria

Article info

Article history:

Accepted December 12, 2005

Published online ahead of
print on ●●●

Keywords:

Prostate cancer
Needle biopsy
Sensitivity
PSA
Clinical significance

Abstract

Objectives: The various prostate biopsy methods are usually compared in terms of the diagnosis rate of prostate cancer. However, the prevalence of cancer in patients with a negative prostatic biopsy is not usually known. We determined the sensitivity and detection rate of 12-core transperineal biopsies in patients not previously investigated for prostate cancer.

Methods: We performed prostate biopsy in 63 patients (median age 67 years) before radical cystoprostatectomy for high-grade bladder cancer. We then assessed the relationships between biopsy result, prostate cancer in the surgical specimen, and other variables.

Results: 17.2% of patients had a positive biopsy and 54% had prostate cancer on definitive histology. Biopsy sensitivity was 32.3% overall, 75% for clinically significant cancers, and 11% for non-significant cancers. Median PSA was 1.2 ng/ml, PSA levels did not correlate with the presence of prostate cancer, the presence of clinically significant cancer, bioptic diagnosis, or prostate volume. Age correlated with risk of cancer.

Conclusions: According to autopsy series, the prevalence of prostate cancer is greater than 50% in males older than 60, yet low PSA levels do not reliably indicate disease absence. The sensitivity of double sextant biopsy is unsatisfactory overall (32%), but acceptable (75%) for diagnosing clinically significant cancer.

© 2005 Published by Elsevier B.V.

* Corresponding author. Division of Urology, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy. Tel. +39 02 57 48 97 46; Fax: +39 02 57 48 97 85.

E-mail address: bernardo.rocco@ieo.it (B. Rocco).

1. Introduction

In 1989 random sextant biopsy was proposed as the gold standard for prostate cancer detection [1]. Since then, several alternative random sample techniques have been proposed [2,3], most of which increase the number of samples or change the sampling pattern in the hope of increasing the rate of diagnosis. Transrectal ultrasound-guided biopsy is the recommended diagnostic method with a minimum of 6–10 systematic, laterally directed cores [4].

A much less widespread alternative to the transrectal approach is the transperineal approach. The actual technique employed, transrectal or transperineal, is probably much less important than where the needles are placed in the prostate [5]; a high cancer detection rate can be achieved by 12-core transperineal prostate biopsy in patients with PSA >4 ng/ml [5], even though the false negative rate of the procedure is still unclear.

The aim of the present study was to determine the false negative rate of a 12-core transperineal prostatic biopsy in order to evaluate sensitivity and negative predictive value in a series not previously investigated for prostate cancer.

2. Materials and methods


2.1. Patients

From May 2002 to October 2004, 63 consecutive patients underwent radical cystoprostatectomy, 41 at the European Institute of Oncology and 22 at the Department of Clinical Urology, University of Milan, for infiltrating or superficial high-grade bladder cancer that was not amenable to conservative treatment. All patients gave informed consent to the pre-surgical biopsy and the use of the surgically removed material for the purposes of this study. Before the operation, digital rectal exploration (DRE) was performed, and PSA levels in the blood were determined by microparticle enzyme immune assay (MEIA) using an AxSYM analyser (Abbott).

Patients were prepared and positioned for surgery according to Emiliozzi et al. [5]. Immediately after induction, transrectal ultrasonography (BK ultrasound, 7.5 MHz probe) was performed. Twelve-core transperineal prostate biopsy was then performed by two urologists (BR and MF) under ultrasound guidance using a Fast-Gun biopsy pistol (Sterylab, Rho, Italy) with a 16-gauge needle. Biopsy cores were nominally 20 mm long. Only the peripheral region of the gland was sampled with six cores per side (Fig. 1). This scheme was adopted based on observations of cancer development within the prostate [6].

2.2. Pathological evaluation

Biopsy material was fixed in 10% formalin, paraffin-embedded, longitudinally sectioned, and stained with



● Far lateral ▲ Transition zone ○ Urethra
 ◐ Lateral (sextant) ● Peripheral zone

Fig. 1 – Coronal prostate section. Diagram illustrating core sites: 3 far lateral and 3 paramedian bilaterally.

hematoxylin and eosin. Length and Gleason score were determined for each core.

After prostatic biopsy, cystoprostatectomy was performed. On the fresh surgical specimen, the individual organs were measured in three dimensions, 10% neutral buffered formalin was then injected into the bladder until fully distended, and the entire specimen was fixed in 5–10 volumes of 10% neutral buffered formalin for 18–24 hours.

After fixation and before inking the surface, the prostate was examined macroscopically for post-surgical clefts in periprostatic tissue, which were noted to avoid their misinterpretation as surgical margins. The prostate was then inked with different colours to facilitate left and right side recognition. The specimen, while still wet, was then briefly immersed in Bouin's fixative and air dried.

The prostate was sampled using the whole-mount section method. Coronal lengths, labelled progressively, were cut perpendicular to the urethral major axis at 0.3 cm intervals from the apex to the junction with seminal vesicles. The first apical length was cut para-sagittally (parallel to the major axis of the urethra) into 0.2–0.3-cm thick sections, labelling the right and the left sides. The lengths were placed in inclusion cassettes and moulds and embedded in paraffin. From the blocks, consecutive 0.3- μ m thick sections were cut, stained in hematoxylin and eosin, and evaluated microscopically. The greatest diameter of each tumour focus was obtained by marking the tumour contour on the glass slide and measuring this distance with a ruler. If tumour size was <0.5 cm, an ocular micrometer was used for measurement. The volume of carcinoma in the entire prostate was determined using the grid method [7,8] and was the sum of the volumes of individual tumour foci. The sum of each area was multiplied by the thickness of the average slice, and the sum of these volumes was multiplied by 1.25 to correct for tissue shrinkage during processing.

2.3. Data analysis

We analysed the correlation between patient age, PSA, prostate volume, biopsy, and surgical specimen outcome.

Biopsy false negative rate was then calculated to define sensitivity and negative predictive value of the procedure.

We assessed sensitivity and negative predictive value even in the subgroup of patients with clinically significant disease, as defined by Epstein et al. in 1998 (non-organ confined disease or Gleason pattern 4 or 5 or tumour volume >0.5 cc) [9].

Qualitative data are presented as frequencies or percentages; continuous data are provided as medians and range and compared using the Kruskal-Wallis test. Exact 95% confidence intervals (95% CI) for proportions were calculated using the binomial distribution. Associations were considered significant for two-sided *p* values of ≤ 0.05 .

3. Results

Mean age of the 63 patients was 67 years (range 48–82); 1 of 63 had positive DRE. Mean PSA of the population was 1.2 ng/ml (range 0.2–9.1) and 7 of 63 had PSA >4 ng/ml. Mean prostatic volume was 34.9 cc (range 11.9–134.8) (Table 1).

Fifty-one (81%, 95% CI, 69–85%) of the 63 patients had a negative biopsy, 11 (17.5%; 95% CI, 9–29%) had a positive biopsy for adenocarcinoma, and 1 (1.5% 95% CI, 0.04–8.5%) had atypically proliferating small acini (ASAP). Urothelial invasion was present on the surgical specimen in two patients with a negative biopsy.

Nominal length of the core was 22 mm. The real median length was 11.2 mm (range 7–20 mm). The median length of the core for positive biopsies was 11.3 mm (range 4–20 mm) for negative biopsies 11.2 mm (range 7–13 mm).

Pathological analysis of the surgical specimen showed 25 (40%; 95% CI, 28–53%) patients without prostate carcinoma, 34 (54%; 95% CI, 41–67%) with prostate carcinoma, and 4 (6%; 95% CI, 2–15%) with high-grade III prostatic intraepithelial neoplasia (PIN).

Median PSA and median prostate volume did not correlate with the presence of prostate cancer in the

biopsy or in the surgical specimen, whereas a higher median age of the patients was associated with the presence of cancer in the biopsy and in the surgical specimen.

Of the 34 patients with prostate carcinoma on the surgical specimen 20 (58%) were pT2a, 12 (35%) were pT2c, two had extraprostatic extension, one pT3apN1, and one pT4N1 (AJCC TNM 6th ed, March 2002) both diagnosed by transperineal biopsy. Gleason score was ≤ 6 , in 27/34 (79%), 7 in four cases, and >7 in the remaining three patients, two of whom had prostate cancer lymph node metastases. Only one patient with Gleason score >6 had a negative prostate biopsy.

Median tumour volume was 0.2 ml ($n = 34$, range 0.001–9.6); None of the 34 patients had cancer located solely in the prostate transition zone.

The sensitivity of prostate biopsy in identifying specimen-confirmed cancer was 32.3% (95% CI, 17–50%), specificity was 100% (95% CI, 86–100%) and negative predictive value was 52.1% (95% CI, 37–67%) (Table 2). The likelihood ratio of prostate cancer for a negative test was 0.68.

Research was also extended to the subgroup of patients with clinically significant cancer according to Epstein's criteria [9].

Twelve (20%; 95% CI 10.2–31%) of the 63 patients had clinically significant cancers. Nine of these were identified by biopsy, thus biopsy sensitivity was 75% (95% CI, 43–94%); specificity was 95.7% (95% CI, 85–99%); and negative predictive value was 93.7% (95% CI, 83–99%). Prostate biopsy was positive in two (9% of total; 95% CI, 1–29%) of the 22 patients with clinically insignificant prostate cancer.

Distribution of prostate cancer volume is reported in Fig. 2. Median PSA did not differ between those with (1.55 ng/ml) and without (1.19 ng/ml) clinically significant disease or those without prostate cancer (1.11 ng/ml) (Kruskal-Wallis, $p = 0.87$) (Fig. 3). However, these three groups differed in age distribution

Table 1 – Relevant patient characteristics related to biopsy and surgical specimen outcome

Patient characteristics		BxP –	BxP +	Kruskall-Wallis	Pca –	Pca +	Kruskall-Wallis
No. Pts	63	51 ^a	11 ^a		25 ^b	34 ^b	
Median age	67 years (48–82)	64	72	$p = 0.008$	63	67.5	$p = 0.022$
Median PSA	1.2 ng/ml (0.2–9.1)	1.5 (0.2–9.1)	0.95 (0.4–6.8)	$p = 0.44$	1.1 (0.2–9.1)	1.2 (0.4–6.8)	$p = 0.44$
PSA >4 ng/ml		6/63	1/63		4/63	3/63	
DRE		0/63	1/63		0/63	1/63	
Median Prostate volume	34.9 ml (11.9–134.8)	33.5 (11.9–134.8)	39.5 (23–60)	$p = 0.32$	33.5 (15.3–66.4)	35.6 (11.9–134.8)	$p = 0.98$

Bxp –: negative biopsy; Bxp +: positive biopsy; Pca –: absence of prostate cancer on the surgical specimen; Pca +: presence of prostate cancer on the surgical specimen.

^a 1 patient had ASAP.

^b 4 patients had PIN III.

Table 2 – Overall and clinically significant^a prostate cancer detection

	Overall	CI 95%	Clinical significant ^a	CI 95%
Sensitivity	32.3%	17–50%	75%	43–94%
Negative predictive value	52.1%	37–67%	93.7%	83–99%
Detection rate	17.5%		14.2%	

^a According to Epstein [9], clinically significant prostate cancer is defined as (volume ≥ 0.5 ml or Gleason score >6 or presence of pattern 4).


Tumor volume distribution in 34 prostatic carcinomas found in specimens from 63 cystoprostatectomy

Fig. 2 – Distribution of prostate cancer volume in the 34 patients (in a series of 63 undergoing cystoprostatectomy) in whom prostate cancer was found. Circles indicate a negative biopsy, triangles a positive biopsy; a solid symbol indicates tumour volume <0.5 ml and an open symbol indicates tumour volume ≥ 0.5 ml.

(median ages 73, 64.5, and 63, respectively; Kruskal-Wallis, $p = 0.003$).

Among the 56 patients with no pre-operative suspicion of prostatic disease (PSA 0–4 ng/ml; negative DRE), 10 (17.8%) had a positive biopsy and 8 of these (14.2% of 56; 95% CI, 6.4–26.2%) had clinically significant disease; 31 (55%, 95% CI: 41.5–68.6%) had cancer in the surgical specimen, and 11 of these (19.6% of 56; 95% CI 10.2–32.4%) had clinically significant disease.

4. Discussion

The detection rate of prostatic cancer in sextant biopsy samples is about 25% in patients with PSA >4 ng/ml [10]. However, repeated biopsies or computer simulations indicate that sextant biopsy is associated with false negative rates of 15–34% [11–15]; autopsy series show prostate cancer in 27% of men aged 30–40, and in more than 60% of men older than 80 [16]. Clearly, sextant biopsy fails to detect a

significant proportion of prostate cancers. Also, although the proportion that develops clinically significant disease is considerably lower than the autopsy prevalence, clinically significant prostate cancers cannot be distinguished from clinically insignificant ones before surgery.

A more pressing clinical problem is the frequent discordance between PSA findings and prostate biopsy findings. Urologists commonly propose a repeated biopsy in patients with negative biopsy histology but high PSA, a proposal justified by the high false negative rate of biopsies. In a recent study Djavan et al. [17] reported that among cancers identified at second biopsy in patients with negative initial biopsy, the proportion that was clinically significant was the same as the proportion of clinically significant cancers identified by the first bioptic set [18]. Assessing the diagnostic accuracy of these modalities is therefore very useful.

In this study we chose the less common trans-perineal approach because biopsy cores, taken along




Fig. 3 – Box plots showing distribution of PSA levels (ng/ml) according to disease status and clinical significance as defined in text. The crosses indicate the means. Ca Clin sig = clinically significant cancer. Ca Non sig = clinically non significant cancer. No Ca = no cancer. Note the large overlap of PSA concentrations.

225 a longitudinal plan parallel to the rectum, enable us
226 to sample only the peripheral zone, whereas in the
227 transrectal technique a part of adenoma happens to
228 also be sampled even in biopsies directed only at the
229 peripheral zone [19]. We chose a 16-gauge needle
230 because detection rate and complications seemed to
231 be proved the same as with an 18-gauge [20], and we
232 are assessing whether there may be advantages in
233 terms of inclusion and cut of the cores. Although the
234 nominal length was 20 mm, the overall mean core
235 length was 11.2 mm, about 3 mm less than the
236 length published by Iczkowski et al. [21] (despite
237 their use of an 18-gauge needle), who had shown a
238 correlation between core length and prostate cancer
239 detection rate with the sextant technique. The
240 difference can probably be partly explained by the
241 fact that Iczkowski calculated the core length
242 summing up to three fragments, while we gave
243 only the length of the longest core of each sample.


244 As for the choice of 12-core sampling, this is in
245 line with the guidelines [4] and with current
246 common clinical practice: according to Descazard
247 et al, up to 70% of urologists sample 10–12 cores [22].

248 Analysing the results of the pathological speci-
249 men, we found that more than 50% of the subjects
250 had prostate cancer, a result in line with autopsy
251 studies. In particular, focusing on the 6th, 7th, and
252 8th decades, representing 94% (59 of 63) of our
253 population, our series revealed a prostate cancer
254 prevalence of 42.8%, 54.5%, and 63.6%, respectively.
255 Sakr et al. analysed autopsy prostate specimens of
256 525 men who died of trauma. Of these 211 were
257 Caucasian and the prevalence of prostate cancer in
258 this group was 44%, 65%, and 83% in the 6th, 7th, and
259 8th decades, respectively [23]. Similarly, in a recent
260 autopsy series Soos et al. found in 139 men without
261 history of urological disease 32.1%, 50%, and 64.7% of
262 prostate cancer in the same age ranges [24].

263 We then assessed the data obtained with the
264 prostatic biopsy.

265 The diagnostic rate was much lower than with
266 other 12-core transperineal techniques such as that
267 of Emiliozzi et al, which had a detection rate of 51%
268 with 12 cores, in a population with PSA >4 ng/ml [5]
269 and Ficarra et al, who had a detection rate of 42.1% in
270 a population of patients with mean PSA of 7.6 ng/ml
271 [25]. Our data were closer (17.5% vs. 15.2%) to those
272 obtained by Thompson et al. who used, in most
273 subjects examined, the transrectal sextant techni-
274 que [26].

275 The two significant tumours undetected by
276 biopsies were localised in the peripheral zone, in
277 the parenchymatous areas, usually sampled with
278 our technique. With respect to this, the needle tract
279 unfortunately skims over the neoplastic area



280 **Fig. 4 – Haemorrhagic area contiguous to clinically**
281 **significant tumour, where neoplastic glands are only**
282 **grazed by the needle tract.**

283 without reaching the tumour (Fig. 4). Notwithstand-
284 ing, we found that the sensitivity of our biopsy
285 technique was 32.3% and the negative predictive
286 value 52.1%. We compared our data with those of
287 Terris [27], who carried out a similar study perform-
288 ing transrectal sextant prostate biopsy before
289 cystoprostatectomy. Our figures are much lower
290 than the 60% and 89.2%, respectively, reported in a
291 smaller series of similar age (43 patients, median
292 71.5 years, range 52–83) to ours (63 patients, median
293 67 years, range 48–82) but characterised by higher
294 PSA levels (median 4.1 ng/ml, range 0.7–10 vs. our
295 1.2 ng/ml, range 0.2–9.1) and fewer patients with
296 prostate cancer (23% compared to our 54%). Further-
297 more, Terris's series was characterized by larger
298 tumour volumes, which facilitate bioptic diagnosis,
299 thereby reducing the false negative rate and
300 increasing the negative predictive value. Six of
301 Terris's 10 cases had tumours >2 ml, while only 2
302 of our 34 cases had similar volumes (7.1 and 9.6 ml).
303 These data may explain the greater sensitivity and
304 lower false negative rate found in the sextant biopsy
305 series compared to our series, which theoretically
306 used a more exhaustive biopsy technique. However,
307 our biopsy method identified clinically significant
308 (sensitivity 75%) more efficiently than total cancers
309 (sensitivity 32%).

310 PSA values in our entire series were low, with
311 median levels <4 ng/ml in all groups, and there were
312 no significant differences between them. This
313 somewhat anomalous finding is nevertheless con-
314 sistent with the results of the recent study by
315 Thompson et al. [26], which found that more than
316 15% of 2,950 men with negative DRE and PSA
317 <4 ng/ml had prostate cancer on sextant biopsy

after a seven year follow-up. Similarly, in a preliminary analysis of ERSPC data, Ciatto et al. [28] found that reduction of the biopsy referral threshold from 4 to 3 ng/ml did not result in a significant reduction in the biopsy diagnostic rate, and that even PSA levels in the 2–3-ng/ml range were associated with cancer diagnosis rates fairly similar to those in men with PSA \geq 4 ng/ml. Ciatto et al. concluded that PSA levels in the 1–10-ng/ml range were not effective predictors of prostate cancer [28]. More recently, Stamey et al. [29] concluded that the role of PSA in prostate cancer diagnostics was over in the USA, emphasizing that serum PSA correlated well with prostate volume, but not with cancer risk.

Nevertheless, the widespread use of PSA testing has undoubtedly increased the prostate cancer diagnosis rate over the short term and has caused a marked stage migration. However, lowering the PSA threshold for biopsy may increase the proportion of indolent cancers identified; using tumour volume $<$ 0.5 cc with no high-grade components as a cut-off to identify indolent tumours, Epstein reported 9–29% of clinical insignificant diseases in T1c prostate cancer in patients with PSA $>$ 4 ng/ml [9], whereas Hautmann reported that 9% of insignificant cancers were found with transrectal sextant biopsy in a population of asymptomatic men with PSA $<$ 4 ng/ml [16].

In our study, 35.3% of the cancers identified in the surgical specimen were clinically significant, and the 12-core transperineal technique identified 75% of these, but only 11% of the clinically insignificant cancers. Considering only patients with PSA $<$ 4 ng/ml and negative DRE, our biopsy technique afforded a greater cancer detection rate (17.8%, 95% CI 6.4–26.2%) than reported by Hautmann et al. (5%, 95% CI 2–10%) using the standard transrectal sextant technique [16]; we also detected a greater proportion of clinically significant cancers: 8/10 (75% 95% CI 43–94%) vs. Hautmann et al.'s 3/11 (27%, 95% CI 6–61%). Moreover, in the Hautmann study, PSA levels (always $<$ 4 ng/ml) were significantly associated with the presence of prostate cancer; in our study there was no such association.

Finally, the increase in the incidence of prostate cancer in prostate biopsy and definitive surgical specimen in relation to age appears in line with the consolidated data in the literature [4,23].

Our study has several possible limitations: the small sample size seems to be the major limitation, therefore our data need to be considered preliminary.

4.1. Population selection

The only way to verify the rate of false negatives is to have a pathologic analysis of the prostate even when

the biopsy is negative. One way to do this is to examine the whole prostate in cadavers following biopsy. Such an approach has not been described previously, and PSA levels are unlikely to be systematically available in autopsy cases. By contrast, use of cystoprostatectomy specimens from bladder cancer patients undergoing prostate biopsy is an established procedure [30], although such patients may not be representative of the general population. In our series this possibility seems unlikely because the frequency of prostate cancers diagnosed in the surgical specimen is closely similar to the autopsy prevalence of prostate cancer in subjects of similar age ranges [23].

4.2. Two different operators

The two urologists who performed the biopsies at different centres followed exactly the same biopsy protocol and achieved closely similar biopsy rates (7/41 or 17% at the European Institute of Oncology; 4/22 or 18% at Clinical Urology University of Milan; $p = 0.95$).

5. Conclusions

This study provides further evidence that prostate cancer is present in more than 50% of elderly males. It also seems to confirm that most of these cancers are not identified by prostate biopsy, even using a more exhaustive sampling technique than the standard sextant biopsy. Importantly, our preliminary data seem to indicate that 12-core biopsy is able to identify about 75% of clinically significant cancers, while only 11% of clinically insignificant cancers are diagnosed. Somewhat anomalously, PSA levels in our series were uninformative, correlating neither with the overall risk of prostate cancer nor with the risk of clinically significant disease. We are trying to collect further data to confirm these preliminary data.

Acknowledgments

We would like to acknowledge Drs. V. Mantovani and F. Ferrando for their valuable collaboration.

References

- [1] Hodge KK, McNeal JE, Terris MK, et al. Random-systematic versus directed ultrasound-guided transrectal core-biopsies of the prostate. *J Urol* 1989;142:71–5.

- 412 [2] Eskew LA, Bare RL, et al. Systematic 5 region prostate 465
413 biopsy is superior to sextant method for diagnosing carcinoma 466
414 of the prostate. *J Urol* 1997;157:199-202. 467
- 415 [3] Nava L, Montorsi F, Consonni PL. Results of a prospective 468
416 randomized study comparing 6, 12, and 18 transrectal 469
417 ultrasound guided sextant biopsies in patients with elevated 470
418 PSA, normal DRE and normal prostatic ultrasound. 471
419 *J Urol* 1997;157:64A. 472
- 420 [4] Aus G, Abbou CC, Bolla M, et al. EAU guidelines on prostate 473
421 cancer. *Eur Urol* 2005 Oct;48(4):546-51. 474
- 422 [5] Emiliozzi P, Longhi S, Scarpone P, et al. The value of a 475
423 single biopsy with 12 transperineal cores for detecting 476
424 prostate cancer in patients with elevated prostate specific 477
425 antigen. *J Urol* 2001;166(3):845-50. 478
- 426 [6] Stamey TA. Making the most out of six systematic sextant 479
427 biopsies. *Urology* 1995;45(1):2-12. 480
- 428 [7] Humphrey PA, Vollmer RT. Intraglandular tumor extent 481
429 and prognosis in prostatic carcinoma: application of a grid 482
430 method to prostatectomy specimens. *Hum Pathol* 1990; 483
431 21:799-804. 484
- 432 [8] Cheng L, Slezak J, Bergstralh EJ, et al. Preoperative pre- 485
433 diction of surgical margin status in prostate cancer 486
434 patients treated by radical prostatectomy. *J Clin Oncol* 487
435 2000;18:2862-8. 488
- 436 [9] Epstein JI, Chan DW, Sokoll LJ, et al. Nonpalpable stage T1c 489
437 prostate cancer: prediction of insignificant disease using 490
438 free/total prostate specific antigen levels and needle 491
439 biopsy findings. *J Urol* 1998;160(Part 2):2407-11. 492
- 440 [10] Ellis WJ, Chetner MP, Preston SD, et al. Diagnosis of pro- 493
441 static carcinoma: the yield of serum prostate specific 494
442 antigen, digital rectal examination and transrectal ultra- 495
443 sonography. *J Urol* 1994;152(5 Part 1):1520-5. 496
- 444 [11] Norberg M, Egevad L, Holmberg L, et al. The sextant 497
445 protocol for ultrasound-guided core biopsies of the prostate 498
446 underestimates the presence of cancer. *Urology* 499
447 1997;50(4):562-6. 500
- 448 [12] Levine MA, Ittman M, Melamed J, et al. Two consecutive 501
449 sets of transrectal ultrasound guided sextant biopsies of 502
450 the prostate for the detection of prostate cancer. *J Urol* 503
451 1998;159:471-6. 504
- 452 [13] Ellis WJ, Brawer MK. Repeat prostate needle biopsy: who 505
453 needs it? *J Urol* 1995;153:1496-8. 506
- 454 [14] Roehrborn CG, Pickens GJ, Sanders JS. Diagnostic yield of 507
455 repeated transrectal ultrasound-guided biopsies stratified 508
456 by specific histopathologic diagnosis and prostate-specific 509
457 antigen levels. *Urology* 1996;47:347-52. 510
- 458 [15] Chen ME, Troncoso P, Johnston DA, et al. Optimization of 511
459 prostate biopsy strategy using computer based analysis. 512
460 *J Urol* 1997;158:2168-75. 513
- 461 [16] Hautmann SH, Conrad S, Henke RP, et al. Detection rate of 514
462 histologically insignificant prostate cancer with systematic 515
463 sextant biopsies and fine needle aspiration cytology. 516
464 *J Urol* 2000;163(6):1734-8. 517
- [17] Djavan B, Mazal P, Zlotta A, et al. Pathological features of 465
prostate cancer detected on initial and repeat prostate 466
biopsy: results of the prospective European Prostate Cancer 467
Detection study. *Prostate* 2001;147(2):111-7. 468
- [18] Djavan B, Remzi M, Marberger M. When and how a pro- 469
static rebiopsy should be performed? *Eur Urol Suppl* 1 470
2002;52-59. 471
- [19] Emiliozzi P, Corsetti A, Tassi B, et al. Best approach for 472
prostate cancer detection: a prospective study on trans- 473
perineal versus transrectal six-core prostate biopsy. 474
Urology 2003;61(5). 475
- [20] Varela R, Rocco B, Matei DV, et al. Valutazione delle 476
caratteristiche diagnostiche di uno schema di biopsia 477
prostatica perineale a doppi sestanti: studio prospettico 478
non randomizzato con aghi 16 vs. 18 gauge. Metodo di 479
valutazione: questionario medico/paziente. Abstract #P95 480
- 78° Congresso nazionale della Società Italiana di Urologia 481
2005. 482
- [21] Iczkowski KA, Casella G, Seppala RJ, et al. Needle core 483
length in sextant biopsy influences prostate cancer detec- 484
tion rate. *Urology* 2002, May;59(5):698-703. 485
- [22] Descazeaud A, Rubin MA, Allory Y. What information are 486
urologists extracting from prostate needle biopsy reports 487
and what do they need for clinical management of pros- 488
tate cancer? *Eur Urol* 2005, Sep 1 [Epub ahead of print]. 489
- [23] Sakr WA, Grignon DJ, Haas GP. Age and racial distribution 490
of prostatic intraepithelial neoplasia. *Eur Urol* 1996;30(2): 491
138-44. 492
- [24] Soos G, Tsakiris I, Szanto J, et al. The prevalence of 493
prostate carcinoma and its precursor in hungary: an 494
autopsy study. *Eur Urol* 2005 Nov;48(5):739-44. 495
- [25] Ficarra V, Novella G, Novara G, et al. The potential impact 496
of prostate volume in the planning of optimal number of 497
cores in the systematic transperineal prostate biopsy. *Eur* 498
Urol 2005, Sep 29 [Epub ahead of print]. 499
- [26] Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of 500
prostate cancer among men with a prostate-specific 501
antigen level <or =4.0 ng per millilitre. *N Engl J Med* 2004; 502
350(22):2239-46. 503
- [27] Terris MK. Sensitivity and specificity of sextant biopsies in 504
the detection of prostate cancer: preliminary report. *Urol-* 505
ogy 1999;54(3):486-9. 506
- [28] Ciatto S, Vis A, Finne P. How to improve the specificity and 507
sensitivity of biopsy technique in screening. *BJU Int* 508
2003;92(Suppl. 2):79-83. 509
- [29] Stamey TA, Caldwell M, McNeal JE. The prostate specific 510
antigen era in the United States is over for prostate 511
cancer: what happened in the last 20 years? *J Urol* 2004, 512
Oct;172(4 Pt 1):1297-301. 513
- [30] Stamey TA, Freiha FS, McNeal JE, et al. Localized prostate 514
cancer. Relationship of tumor volume to clinical signifi- 515
cance for treatment of prostate cancer. *Cancer* 1993;71: 516
933-8. 517